CDE official website today announced that 10 new types of Class 1 drugs have been approved clinically.

Turn fromAccording to the official website of the Drug Review Center (CDE) of the State Drug Administration of China, 10 new drugs have been approved for clinical treatmentthese new drugs in the research are targets of TYK2 inhibitors, PI3K inhibitors, Bcl-2 inhibitors, IL-17 antibodies, etc., from Pfizer, East Sunshine Pharmaceuticals, Arnold Pharmaceuticals, Regency Pharmaceuticals, Corning Jerry, Huahai Pharmaceuticals, Hengrui Pharmaceuticals, etcClinical Trials Implied License (Data Source: CDE) Pfizer: TYK2 inhibitor PF-06826647 PF-06826647 is a TYK2 inhibitor developed by Pfizer and has progressed to Phase 2 clinicallyTYK2 is a member of the JAK family and plays an important role in mediatuating IL-12, IL-23 and type 1 interferon signalsaccording to Pfizer's official website, the product is intended to develop indications as inflammatory and autoimmune diseasesthis time, the product was implicitly licensed by clinical trials in China to develop an indication of moderate to severe ulcerative colitisArno Medicine: PI3K inhibitor AN2025AN2025 (buparlisib) is an oral pan-PI3K inhibitor that can be targeted at all Class I PI3K subtypes with tumor immunitythe product was originally developed by Novartis, and Arnold Pharmaceuticals acquired its global exclusive interest in 2018 by signing a global licensing agreement, based on the product's previously completed Global Phase 2 clinical phase, is used in conjunction with yew alcohol in patients with head and neck squamous cell carcinoma with a median survival time of up to 10.4 monthsearlytrials have also shown that AN2025 has therapeutic potential for tumors withno-non-response to PD-1 drugs or PD-1 tolerancenote that the FDA has granted the drug fast-track eligibilitythis AN2025 approved clinical trial in China to develop an indication of recurrent or metastatic head and neck squamous cell carcinomaReinvasive Medicine: Bcl-2 Inhibitor FCN-338 FCN-338 is a Bcl-2 Selective Small Molecule Inhibitoraccording to the announcement of the re-creation of pharmaceutical, the product by its independent research and development, the cumulative investment in research and development has exceeded 260,000 yuanBCL-2, known as selective B-cell lymphoma factor-2, plays an important role in apoptosis and is overexpressed in certain types of cancer, associated with the formation of drug resistance, and is a new target for the treatment of blood cancers Bcl-2 inhibitors can kill tumor cells by inhibiting BCL-2 function and restoring the stage of procedural death of tumor cells FCN-338 has been granted implicit permission from clinical trials to be used to treat malignancies in the hematologic system Corning Jerry: Coagulation Factor Product KN057 Injection KN057 is an innovative coagulation-related biopharmaceutical developed based on protein engineering and antibody screening technology for the treatment of blood diseases this product was implicitly licensed in clinical trials in China to develop hemophilia A and haemophilia B as a companion or non-inhibition of indications haemophilia is a rare hereditary haemorrhagic disease, the lack of coagulation factor in the patient's body, the need for long-term infusion coagulation factor Huahai Pharmaceuticals: IL-17 antibody HB0017 injection hb0017 is a single-clone antibody targeting interleukin-17 (IL-17), has been obtained in China moderate to severe plaque psoriasis, strong scoliosis, this time obtained the clinical trial implicitly approved for the adaptation of psoriasis arthritis studies show that IL-17 is an important inflammatory factor that plays an important role in the pathological process esortization of various autoimmune diseases note that the product was approved for clinical trials in the United States in April this year East Sunshine Pharmaceuticals: PI3K inhibitor HEC89736PTSA- 0.5H2O heC89736PTSA 0.5H2O is an oral high-selective PI3K inhibitor developed by Dongsun Pharmaceuticals studies show that PI3K is an important target for the treatment of a wide range of immune diseases, and plays an important role in regulating adaptive immune system cells and innate immune systems this time, the HEC89736PTSA-0.5H2O tablets are subject to clinical trial symbiotic indications such as chronic lymphocytic leukemia, small lymphocyte lymphoma, and follicular lymphoma in addition, the clinical trial has been tacitly approved by the new class of new drugs: Hengrui Pharmaceuticals' bio-new drug SHR-1703 injection, intended to be used to treat eosinophil sacintic elevated diseases: such as eosinophilic severe asthma; The late-stage solid tumor to be used for the treatment of c-MET abnormality; Fuxin Pharmaceuticals WXFL10203614 tablets for the treatment of moderate to severe active rheumatoid arthritis; and The Recombinant Anti-Rabies Humanized Monoclonal Antibody Injection of Xing-Men Bio, intended for post-exposure prophylaxis of rabies original title: Ten new class 1 drugs approved clinical, from Pfizer, Dongsun, Corning Jerry, Huahai Pharmaceuticals, etc to pay attention to the "Drug MingKangd" WeChat public number.